Three independent discounted-cash-flow-style models value Ligand Pharmaceuticals Inc. every trading day. 0 of 3 currently price LGND above its market price.
| Free Cash Flow model | $-341.75 |
| Excess Profit model | $-106.99 |
| Residual Earnings model | $-3.42 |
| Dividend Discount model | — |
| Piotroski F-Score | 4 / 9 |
| Return on invested capital | +2.1% |
| Net debt / EBITDA | 8.1× |
| Gross margin | +100.0% |
| Revenue CAGR | +11.0% |
| Cash conversion | 0.4× |
| Dividend yield | — |
| Buyback yield | -5.7% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open LGND in StockKitty